Clinical Trial Update: Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing EGb 761® versus placebo for cognitive impairment in adults with relapsing-remitting multiple sclerosis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• EGb 761 (Ginkgo biloba extract)

Snippet

Sponsor: Ipsen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED